The Asia Pacific Telmisartan Market would witness market growth of 7.2% CAGR during the forecast period (2020-2026). Telmisartan is considered as a prescription medication, which is frequently suggested to ease down and broaden blood vessels in persons having elevated blood pressure.
Telmisartan means a set of drugs called as angiotensin II receptor blockers (ARBs). Telmisartan could be utilized alone or in combination with other medications like hydrochlorothiazide with an aim to treat elevated blood pressure.
The growth of the Telmisartan market would be supplemented by the increasing number of supportive government policies for hypertension management. For example, in December 2017, the Secretary, Ministry of Health and Family Welfare (MOHFW) and Secretary, Department of Health Research (DHR) and Director General, Indian Council of Medical Research (ICMR) introduced, ‘India Hypertension Management Initiative (IHMI)’. The IHMI focuses to decrease death & disability associated with cardiovascular disease (CVD), by enhancing control over elevated blood pressure (hypertension), lowering down salt consumption from food, and cutting down artificial trans-fats, which are supporting the risks for creating CVD.
The Hypertension market dominated the Malaysia Telmisartan Market by Indication in 2019, thereby, achieving a market value of $45.1 million by 2026. The Cardiovascular Risk Reduction market is expected to witness a CAGR of 9% during (2020 - 2026).
Based on Indication, the market is segmented into Hypertension and Cardiovascular Risk Reduction. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: Telmisartan Market in Asia Pacific is expected to register a CAGR of 7.2% during the forecast period (2020-2026)
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Aurobindo Pharma Limited, Boehringer Ingelheim International GmbH, Cipla Limited, GlaxoSmithKline PLC (GSK), Mylan N.V., Sanofi S.A., Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd., and Cadila Healthcare Ltd. (Zydus Cadila).
Scope of the Study
Market Segments Covered in the Report:
By Indication
- Hypertension
- Cardiovascular Risk Reduction
By Distribution Channel
- Hospital Pharmacies
- Drug Stores & Retail Pharmacies
- Online Pharmacies
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Abbott Laboratories
- Aurobindo Pharma Limited
- Boehringer Ingelheim International GmbH
- Cipla Limited
- GlaxoSmithKline PLC (GSK)
- Mylan N.V.
- Sanofi S.A.
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceuticals Industries Ltd.
- Cadila Healthcare Ltd. (Zydus Cadila)
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Telmisartan Market, by Indication
1.4.2 Asia Pacific Telmisartan Market, by Distribution Channel
1.4.3 Asia Pacific Telmisartan Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Asia Pacific Telmisartan Market by Indication
3.1 Asia Pacific Hypertension Market by Country
3.2 Asia Pacific Cardiovascular Risk Reduction Market by Country
Chapter 4. Asia Pacific Telmisartan Market by Distribution Channel
4.1 Asia Pacific Hospital Pharmacies Market by Country
4.2 Asia Pacific Drug Stores and Retail Pharmacies Market by Country
4.3 Asia Pacific Online Pharmacies Market by Country
Chapter 5. Asia Pacific Telmisartan Market by Country
5.1 China Telmisartan Market
5.1.1 China Telmisartan Market by Indication
5.1.2 China Telmisartan Market by Distribution Channel
5.2 India Telmisartan Market
5.2.1 India Telmisartan Market by Indication
5.2.2 India Telmisartan Market by Distribution Channel
5.3 Japan Telmisartan Market
5.3.1 Japan Telmisartan Market by Indication
5.3.2 Japan Telmisartan Market by Distribution Channel
5.4 South Korea Telmisartan Market
5.4.1 South Korea Telmisartan Market by Indication
5.4.2 South Korea Telmisartan Market by Distribution Channel
5.5 Malaysia Telmisartan Market
5.5.1 Malaysia Telmisartan Market by Indication
5.5.2 Malaysia Telmisartan Market by Distribution Channel
5.6 Malaysia Telmisartan Market
5.6.1 Malaysia Telmisartan Market by Indication
5.6.2 Malaysia Telmisartan Market by Distribution Channel
5.7 Rest of Asia Pacific Telmisartan Market
5.7.1 Rest of Asia Pacific Telmisartan Market by Indication
5.7.2 Rest of Asia Pacific Telmisartan Market by Distribution Channel
Chapter 6. Company Profiles
6.1 Abbott Laboratories
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expense
6.2 Aurobindo Pharma Limited
6.2.1 Company Overview
6.2.1 Financial Analysis
6.2.2 Regional Analysis
6.2.3 Research & Development Expense
6.2.4 Recent strategies and developments:
6.2.4.1 Approvals:
6.2.4.2 Acquisition and Mergers:
6.3 Boehringer Ingelheim International GmbH
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Research & Development Expense
6.3.5 Recent strategies and developments:
6.3.5.1 Approvals:
6.3.5.2 Partnerships, Collaborations, and Agreements:
6.4 Cipla Limited
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Regional Analysis
6.4.4 Research & Development Expense
6.4.5 Recent strategies and developments:
6.4.5.1 Partnerships, Collaborations, and Agreements:
6.4.5.2 Approvals:
6.5 GlaxoSmithKline PLC (GSK)
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Segmental and Regional Analysis
6.5.4 Research & Development Expense
6.6 Mylan N.V.
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Regional Analysis
6.6.4 Research & Development Expense
6.6.5 Recent strategies and developments:
6.6.5.1 Product Launches and Product Expansions:
6.7 Sanofi S.A.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Segmental and Regional Analysis
6.7.4 Research & Development Expense
6.8 Sun Pharmaceutical Industries Ltd.
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Regional Analysis
6.8.4 Research & Development Expense
6.8.5 Recent strategies and developments:
6.8.5.1 Approvals:
6.8.5.2 Product Launches and Product Expansions:
6.9 Teva Pharmaceutical Industries Ltd.
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Regional Analysis
6.9.4 Research & Development Expenses
6.9.5 Recent strategies and developments:
6.9.5.1 Approvals:
6.9.5.2 Product Launches and Product Expansions:
6.10. Cadila Healthcare Ltd. (Zydus Cadila)
6.10.1 Company Overview
6.10.2 Financial Analysis
6.10.3 Segmental and Regional Analysis
6.10.4 Research & Development Expense
6.10.5 Recent strategies and developments:
6.10.5.1 Approvals:
TABLE 1 Asia Pacific Telmisartan Market, 2016 - 2019, USD Million
TABLE 2 Asia Pacific Telmisartan Market, 2020 - 2026, USD Million
TABLE 3 Asia Pacific Telmisartan Market by Indication, 2016 - 2019, USD Million
TABLE 4 Asia Pacific Telmisartan Market by Indication, 2020 - 2026, USD Million
TABLE 5 Asia Pacific Hypertension Market by Country, 2016 - 2019, USD Million
TABLE 6 Asia Pacific Hypertension Market by Country, 2020 - 2026, USD Million
TABLE 7 Asia Pacific Cardiovascular Risk Reduction Market by Country, 2016 - 2019, USD Million
TABLE 8 Asia Pacific Cardiovascular Risk Reduction Market by Country, 2020 - 2026, USD Million
TABLE 9 Asia Pacific Telmisartan Market by Distribution Channel, 2016 - 2019, USD Million
TABLE 10 Asia Pacific Telmisartan Market by Distribution Channel, 2020 - 2026, USD Million
TABLE 11 Asia Pacific Hospital Pharmacies Market by Country, 2016 - 2019, USD Million
TABLE 12 Asia Pacific Hospital Pharmacies Market by Country, 2020 - 2026, USD Million
TABLE 13 Asia Pacific Drug Stores and Retail Pharmacies Market by Country, 2016 - 2019, USD Million
TABLE 14 Asia Pacific Drug Stores and Retail Pharmacies Market by Country, 2020 - 2026, USD Million
TABLE 15 Asia Pacific Online Pharmacies Market by Country, 2016 - 2019, USD Million
TABLE 16 Asia Pacific Online Pharmacies Market by Country, 2020 - 2026, USD Million
TABLE 17 Asia Pacific Telmisartan Market by Country, 2016 - 2019, USD Million
TABLE 18 Asia Pacific Telmisartan Market by Country, 2020 - 2026, USD Million
TABLE 19 China Telmisartan Market, 2016 - 2019, USD Million
TABLE 20 China Telmisartan Market, 2020 - 2026, USD Million
TABLE 21 China Telmisartan Market by Indication, 2016 - 2019, USD Million
TABLE 22 China Telmisartan Market by Indication, 2020 - 2026, USD Million
TABLE 23 China Telmisartan Market by Distribution Channel, 2016 - 2019, USD Million
TABLE 24 China Telmisartan Market by Distribution Channel, 2020 - 2026, USD Million
TABLE 25 India Telmisartan Market, 2016 - 2019, USD Million
TABLE 26 India Telmisartan Market, 2020 - 2026, USD Million
TABLE 27 India Telmisartan Market by Indication, 2016 - 2019, USD Million
TABLE 28 India Telmisartan Market by Indication, 2020 - 2026, USD Million
TABLE 29 India Telmisartan Market by Distribution Channel, 2016 - 2019, USD Million
TABLE 30 India Telmisartan Market by Distribution Channel, 2020 - 2026, USD Million
TABLE 31 Japan Telmisartan Market, 2016 - 2019, USD Million
TABLE 32 Japan Telmisartan Market, 2020 - 2026, USD Million
TABLE 33 Japan Telmisartan Market by Indication, 2016 - 2019, USD Million
TABLE 34 Japan Telmisartan Market by Indication, 2020 - 2026, USD Million
TABLE 35 Japan Telmisartan Market by Distribution Channel, 2016 - 2019, USD Million
TABLE 36 Japan Telmisartan Market by Distribution Channel, 2020 - 2026, USD Million
TABLE 37 South Korea Telmisartan Market, 2016 - 2019, USD Million
TABLE 38 South Korea Telmisartan Market, 2020 - 2026, USD Million
TABLE 39 South Korea Telmisartan Market by Indication, 2016 - 2019, USD Million
TABLE 40 South Korea Telmisartan Market by Indication, 2020 - 2026, USD Million
TABLE 41 South Korea Telmisartan Market by Distribution Channel, 2016 - 2019, USD Million
TABLE 42 South Korea Telmisartan Market by Distribution Channel, 2020 - 2026, USD Million
TABLE 43 Malaysia Telmisartan Market, 2016 - 2019, USD Million
TABLE 44 Malaysia Telmisartan Market, 2020 - 2026, USD Million
TABLE 45 Malaysia Telmisartan Market by Indication, 2016 - 2019, USD Million
TABLE 46 Malaysia Telmisartan Market by Indication, 2020 - 2026, USD Million
TABLE 47 Malaysia Telmisartan Market by Distribution Channel, 2016 - 2019, USD Million
TABLE 48 Malaysia Telmisartan Market by Distribution Channel, 2020 - 2026, USD Million
TABLE 49 Malaysia Telmisartan Market, 2016 - 2019, USD Million
TABLE 50 Malaysia Telmisartan Market, 2020 - 2026, USD Million
TABLE 51 Malaysia Telmisartan Market by Indication, 2016 - 2019, USD Million
TABLE 52 Malaysia Telmisartan Market by Indication, 2020 - 2026, USD Million
TABLE 53 Malaysia Telmisartan Market by Distribution Channel, 2016 - 2019, USD Million
TABLE 54 Malaysia Telmisartan Market by Distribution Channel, 2020 - 2026, USD Million
TABLE 55 Rest of Asia Pacific Telmisartan Market, 2016 - 2019, USD Million
TABLE 56 Rest of Asia Pacific Telmisartan Market, 2020 - 2026, USD Million
TABLE 57 Rest of Asia Pacific Telmisartan Market by Indication, 2016 - 2019, USD Million
TABLE 58 Rest of Asia Pacific Telmisartan Market by Indication, 2020 - 2026, USD Million
TABLE 59 Rest of Asia Pacific Telmisartan Market by Distribution Channel, 2016 - 2019, USD Million
TABLE 60 Rest of Asia Pacific Telmisartan Market by Distribution Channel, 2020 - 2026, USD Million
TABLE 61 Key Information – Abbott Laboratories
TABLE 62 key information – Aurobindo Pharma Limited
TABLE 63 Key Information – Boehringer Ingelheim International GmbH
TABLE 64 Key Information – Cipla Limited
TABLE 65 Key Information – GlaxoSmithKline PLC (GSK)
TABLE 66 Key Information – Mylan N.V.
TABLE 67 Key Information – Sanofi S.A.
TABLE 68 Key Information – Sun Pharmaceutical Industries Ltd.
TABLE 69 Key Information – Teva Pharmaceuticals Industries Ltd.
TABLE 70 Key Information – Cadila Healthcare Ltd.
List of Figures
FIG 1 Methodology for the research